The issue with CU64 is not what it’s capable of, it’s the commercial viability due to supply chain issues and significant clinical deployment issues.
Even if clinicians wanted CU 100% of the time you have to get it to them in a cost effective, safe, consistent easy to use way. The benefit and altered patient treatment would have to be substantial vs GA however I don’t believe that to be the case, at least there is no current evidence. LU can pick up small legions to.
Agreed it’s not either or however I can’t see CU taking off given the reasons above.
Cheers
Understanding Telix, page-1404
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.61 |
Change
0.130(0.70%) |
Mkt cap ! $6.227B | |||
| Open | High | Low | Value | Volume |
| $18.69 | $18.80 | $18.37 | $19.72M | 1.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161 | $18.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.62 | 450 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |